RIAltO: A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL

Trial Profile

RIAltO: A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2016

At a glance

  • Drugs Ofatumumab (Primary) ; Bendamustine; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms RIAltO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Feb 2016 Accrual to date is 65% as reported by United Kingdom Clinical Research Network.
    • 25 Feb 2016 Planned End Date changed from 1 Dec 2017 to 30 Apr 2017 as reported by United Kingdom Clinical Research Network
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top